TRIA Preps FDA Submission For OTC Skin Rejuvenating Laser, Files For IPO
This article was originally published in The Tan Sheet
Executive Summary
The aesthetic device maker plans to file a 510(k) this year with FDA for its OTC, non-ablative laser to treat facial wrinkles, supported in part by proceeds from an IPO worth up to $86.3 million. The hand-held device restricts a laser beam to fine “spot sizes” surrounded by untreated tissue.